PMID- 11806812
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1468-6708 (Print)
IS  - 1468-6694 (Electronic)
IS  - 1468-6694 (Linking)
VI  - 2
IP  - 6
DP  - 2001
TI  - Debate: Statins should be used in patients with heart failure.
PG  - 268-270
AB  - Treatment to prevent progression of heart failure has been targeted to reverse 
      the consequences of heart failure and to a lesser extent the cause - the 
      atherosclerotic plaque itself. Less than 50% of patients with heart failure are 
      treated with lipid intervention. Heart failure (New York Heart Association [NYHA] 
      functional classes I and II) is associated with an increase in low-density 
      lipoproteins (LDL) and triglycerides while high-density lipoproteins (HDL) is 
      lowered. In NYHA class IV, cholesterol is reduced due to depressed production in 
      the liver. Although lipoproteins, especially LDL and HDL, may have some 
      protective effect in binding and neutralising endotoxins released from the 
      intestine during terminal heart failure, observational studies in patients with 
      heart failure strongly suggest that lipid modification with statins may reduce 
      progression of heart failure as well as reducing heart failure mortality.
FAU - Kjekshus, John
AU  - Kjekshus J
AD  - Department of Cardiology, Rikshospitalet, Oslo, Norway. 
      john.kjekshus@klinmed.uio.no
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Control Trials Cardiovasc Med
JT  - Current controlled trials in cardiovascular medicine
JID - 100968052
PMC - PMC64828
EDAT- 2002/01/25 10:00
MHDA- 2002/01/25 10:01
PMCR- 2001/11/28
CRDT- 2002/01/25 10:00
PHST- 2002/01/25 10:00 [pubmed]
PHST- 2002/01/25 10:01 [medline]
PHST- 2002/01/25 10:00 [entrez]
PHST- 2001/11/28 00:00 [pmc-release]
AID - cvm-2-6-268 [pii]
AID - 10.1186/cvm-2-6-268 [doi]
PST - ppublish
SO  - Curr Control Trials Cardiovasc Med. 2001;2(6):268-270. doi: 10.1186/cvm-2-6-268.